Leipzig

Running trials

• Recruiting

  A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

  NCT07498426· Phase 3· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

  NCT07549516· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Source

• Recruiting

  Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

  NCT07102628· Phase 3· Source

• Active, not recruiting

  A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

  NCT06551519· Source

• Recruiting

  Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

  NCT06517719· Source

• Recruiting

  Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  NCT05948943· Phase 2/3· Source

• Active, not recruiting

  Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

  NCT05552469· Phase 1· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic myeloid leukaemia1 recruiting
• Multiple sclerosis1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care

  NCT06004453· Source

• Recruiting

  A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

  NCT05344469· Source

• Completed

  Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Phase 4· Source

• Completed

  A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

  NCT05362903· Source

• Completed

  Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

  NCT04679935· Phase 4· Source

• Completed

  Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

  NCT04632927· Phase 3· Source

• Completed

  Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

  NCT04543331· Source

• Terminated

  A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

  NCT04150029· Phase 2· Source

• Terminated

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Phase 3· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Phase 2· Source

• Completed

  A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

  NCT06311383· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Source

• Completed

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Phase 2· Source